SCHEDULE 13G/A: BlackRock Boosts ANI Pharma Stake to 11.3%
Beneficial Ownership Report
BlackRock, Inc. has reported an 11.3% beneficial ownership stake in ANI Pharmaceuticals Inc. common stock, holding 2,517,424 shares.
Summary
- BlackRock, Inc. beneficially owns 2,517,424 shares of ANI Pharmaceuticals Inc. common stock.
- This ownership represents 11.3% of the class of securities.
- BlackRock, Inc. holds sole voting power over 2,482,925 shares and sole dispositive power over 2,517,424 shares.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
- Various BlackRock subsidiaries, including BlackRock Fund Advisors, contribute to this aggregate beneficial ownership, with BlackRock Fund Advisors beneficially owning 5% or greater of the outstanding shares.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that inherently indicates a positive or negative sentiment regarding the issuer's performance or outlook.
Positives
- Increased institutional ownership by a major asset manager like BlackRock can signal confidence in the company's long-term prospects.
- The acquisition of shares is stated to be in the ordinary course of business, indicating a passive investment strategy rather than an activist one.
Risks
- No specific risks related to ANI Pharmaceuticals Inc. operations or financial health are detailed in this beneficial ownership report.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding ANI Pharmaceuticals Inc.'s future performance or strategic direction.
Management Comments
- Spencer Fleming, Managing Director of BlackRock, Inc., certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Industry Context
This filing reflects a significant institutional investment in the pharmaceutical sector, indicating continued interest from major asset managers in companies like ANI Pharmaceuticals. Such disclosures are common as large funds adjust their portfolio holdings.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake by BlackRock, Inc. may influence market perception and investor confidence in ANI Pharmaceuticals Inc.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Date of previous Power of Attorney, which was revoked. |
| 2025-01-21 | Date the new Power of Attorney was executed by BlackRock, Inc. |
| 2025-09-30 | Date of event which requires filing of this statement. |
| 2025-10-17 | Date of filing of this Schedule 13G Amendment No. 12. |
Keywords
ANI Pharmaceuticals, BlackRock, Institutional Ownership, Common Stock, SEC Filing, Schedule 13G, Beneficial Ownership, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.